Compare Recursion Pharmaceuticals Inc (RXRX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Sanofi SA — how do they compare? Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B), while Sanofi SA trades at $43.7 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 57.6× Recursion Pharmaceuticals Inc's market cap, and Sanofi SA pays a 5.55% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SNY | |
|---|---|---|
Market Cap | $1.81B | $104.30B |
Sector | Health | Health |
52-Week High | $6.79 | $52.34 |
52-Week Low | $2.84 | $41.33 |
Enterprise Value | $1.33B | $124.19B |
Dividend Yield | — | 5.55% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
